【摘要】 目的探讨卡维地洛联合厄贝沙坦治疗慢性心力衰竭的疗效及安全性。方法回顾性分析我院2011年3月~2013年3月收治的106例慢性心力衰竭患者的临床资料,根据治疗用药分为观察组(61例)与对照组(45例),对照组患者采用美托洛尔联合厄贝沙坦治疗,观察组患者采用卡维地洛联合厄贝沙坦治疗,比较两组患者的治疗效果、心功能及不良反应发生率。结果观察组患者治疗有效率为83.6%,明显优于对照组(66.7%),且观察组患者不良反应发生率低于对照组,观察组治疗后患者各项心功能指标均优于对照组,两组数据比较差异有统计学意义(P<0.05)。结论卡维地洛联合厄贝沙坦治疗心力衰竭效果满意,并发症少,安全有效,值得临床推广。更多还原

【Abstract】 Objective To explore clinical effect and safety of carvedilol and irbesartan treating chronic heart failure.Methods 106 patients with chronic heart failure treated in our hospital from March 2011 to March 2012 were collected retrospectively and divided into the observation group(61 cases) and control group(45 cases). The control group were treated with metoprolol and irbesartan, and the observation group were treated with carvedilol and Irbesartan. The treatment effect, adverse reaction and heart function of two groups were compared. Results The effective rate of the observation group was 83.6%, and that of the control group was 66.7%, the untoward effect date of observation group was better than the control group. Rehabilitation of cardiac function in the observation group was better evidently than that of the control group, which all had statistical significance(all P < 0.05). Conclusion The treatment of chronic heart failure with carvedilol and irbesartan have better clinical result, and have low incidence rate of complications,which issafety and worthy of clinical promotion.更多还原